← Product Code [GJS](/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GJS) · K021923 # INRATIO SELF-TEST (K021923) _Hemosense, Inc. · GJS · Oct 24, 2002 · Hematology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GJS/K021923 ## Device Facts - **Applicant:** Hemosense, Inc. - **Product Code:** [GJS](/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GJS.md) - **Decision Date:** Oct 24, 2002 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 864.7750 - **Device Class:** Class 2 - **Review Panel:** Hematology ## Indications for Use The HemoSense INRatio is an in vitro diagnostic system that provides a quantitative prothrombin time results, expressed in seconds and as an International Normalized Ratio (INR). It uses fresh capillary whole blood and is intended for is intended for quantitative prothrombin time testing of fresh, capillary whole blood for monitoring of oral anticoagulation therapy by trained patients or their caregivers, on the prescription or other order of a treating physician. ## Device Story System monitors oral anticoagulation therapy via PT/INR testing. Input: drop of fresh capillary whole blood applied to test strip. Operation: blood drawn into three-channel test strip; one channel performs PT test, two channels perform internal control tests. Electrodes detect clot formation; meter calculates PT and INR. Output: PT and INR results displayed on screen; error message displayed if internal controls fail. Used in home setting by trained patients or caregivers. Benefits: enables patient self-monitoring of anticoagulation therapy under physician prescription. ## Clinical Evidence Performance data demonstrated that the INRatio system performs equivalently when used by trained lay users and healthcare professionals. Both user populations generated results equivalent to an established reference method. ## Technological Characteristics In vitro diagnostic system using a modified one-stage prothrombin time test. Features a three-channel test strip with integrated electrodes for clot detection. Meter-based calculation of PT and INR. No external quality control required; internal controls integrated into test strip channels. ## Regulatory Identification A prothrombin time test is a device used as a general screening procedure for the detection of possible clotting factor deficiencies in the extrinsic coagulation pathway, which involves the reaction between coagulation factors III and VII, and to monitor patients receiving coumarin therapy (the administration of one of the coumarin anticoagulants in the treatment of venous thrombosis or pulmonary embolism). ## Predicate Devices - INRatio ([K021923](/device/K021923.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ KO21923 # OCT 2 4 2002 ### Appendix F 510(k) Summary : 上 | Introduction: | According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence. | |--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 1. Submitter's name address, contact | HemoSense
600 Valley Way
Miilpitas, CA 95035
(408) 719-1393 (phone)
(408) 719-1184 (fax) | | | Contact person: Judith Blunt | | | Date prepared: June 10, 2002 | | 2. Device name | Common or Usual Name: Prothrombin Time Test | | | Classification Name: Prothrombin Time Test | | | Trade or Proprietary Name: INRatio | | 3. Predicate device: | The INRatio System: device for testing Prothrombin Time and INR in whole blood. | | 4. Device description: | The INRatio Prothrombin Time Monitoring System uses a modified version of the one-stage prothrombin time test. After a drop of blood is applied to the test strip, it is drawn into the test area and mixed with reagents that cause coagulation to begin. The test area on the test strip is separated into three channels, each of which contains electrodes for detection of the blood clot. One channel contains the reagents to perform the prothrombin time test on the blood sample. The other two channels contain the reagents to run control tests. No external quality control tests are required for the INRatio system. The meter monitors the reactions, and calculates the PT and INR for the blood sample, which are reported on the display. If the control results are not within a set range, it indicates a problem with the test and an error message is reported on the display instead of a result. The INRatio is the same as the INRatio, except that the labeling has been modified for readability by the lay user. | {1}------------------------------------------------ - 5. Intended use: . The INRatio is intended for quantitative prothrombin time testing of fresh, capillary whole blood for monitoring of oral anticoagulation therapy by trained patients or their caregivers, on the prescription or other order of a treating physician. - 6. Comparison to The INRatio is substantially equivalent in materials, design and intended use to other products predicate device that measure Prothrombin Time INR in human blood. Most notably, it is substantially equivalent to the INRatio, manufactured by HemoSense. In fact, it is identical in materials, design and function to the INRAtio, but the labeling has been changed for physician directed, self-test use. - 7. Summary of The INRatio System was found to perform equivalently when used by trained lay users and performance data healthcare professionals. Furthermore, both user populations generated results found to be equivalent to an established reference method. {2}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines representing its wings and tail feathers. The eagle is positioned to the right of a circular border containing the text "DEPARTMENT OF HEALTH & HUMAN SERVICES U.S.A.". The text is arranged around the circle's perimeter. ockville MD 20850 Ms. Judith Blunt Director of Clinical Affairs HemoSense, Inc. 600 Valley Way Milpitas, California 95035 Re: k021923 Trade/Device Name: HemoSense INRatio Self-Test PT Monitoring System Regulation Number: 21 CFR § 864.7750 Regulation Name: Prothrombin Time Test Regulatory Class: II Product Code: GJS Dated: August 29, 2002 Received: August 30, 2002 Dear Ms. Blunt: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Under Section 522(a) of the act, manufacturers of certain Class II or Class III devices that meet certain criteria may be ordered to conduct Postmarket Surveillance (PS) of that device. We are considering ordering PS for the HemoSense INRation Self-Test System. Please contact Valerie Dada at 301-594-1243 within 15 days of receipt of this letter to arrange a meeting to discuss the objective and design of a PS plan for your device." Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act {3}------------------------------------------------ Page 2 - Ms. Judith Blunt or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.qov/cdrh/dsma/dsmamain.html Sincerely yours, Steven Sutman Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ Appendix G. Indications for Use Statement June 10, 2002 #### PREMARKET NOTIFICATION INDICATIONS FOR USE STATEME (As required by 21 CFR 807.87(i)) ## 510(K) Number: KO21923 Device Name: HemoSense INRatio PT Monitoring System The HemoSense INRatio is an in vitro diagnostic system that provides a quantitative prothrombin time results, expressed in seconds and as an International Normalized Ratio (INR). It uses fresh capillary whole blood and is intended for is intended for quantitative prothrombin time testing of fresh, capillary whole blood for monitoring of oral anticoagulation therapy by trained patients or their caregivers, on the prescription or other order of a treating physician. #### PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED Signed: Judith Blunt Name: Judith Blunt Position: Director of Clinical Affairs and Product Support Date: June 10, 2002 Prescription Home-use --- **Source:** [https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GJS/K021923](https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GJS/K021923) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com